The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients
Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Participants
2.2. Procedures
2.3. Cognitive Testing
2.4. Statistical Analyses
3. Results
3.1. Description of the Total Sample
3.2. Division of the Total Sample into Two Groups and Their Comparison
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
CRCI | cancer- or chemotherapy-related cognitive impairment |
HL | Hodgkin lymphoma |
IF RT | involved-field radiation therapy |
ABVD | adriamycin, bleomycin, vinblastine, and dacarbazine |
Gy | Gray |
BEACOPP | bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone |
BEACOPPesc | BEACOPP escalated |
NIMH | National Institute of Mental Health |
FNKV | University Hospital Kralovske Vinohrady |
AVLT | Auditory Verbal Learning Test |
ROCFT | Rey–Osterrieth Complex Figure Test |
TMT | Trail Making Test |
VFT | Verbal Fluency Test |
WMS-IIIa | Wechsler Memory Scale—third edition, abbreviated |
CPT-3 | Continuous Performance Test 3 |
WAIS-III | Wechsler Adult Intelligence Scale—third edition |
BDI-II | Beck Depression Inventory |
BDA-II | Beck Anxiety Inventory |
HAM-D | Hamilton Depression Rating Scale |
HAM-A | Hamilton Anxiety Rating Scale |
WHOQOL-BREF | Czech version of the World Health Organization Quality of Life |
M | mean |
SD | standard deviation |
N | number |
P | p-value |
Appendix A
T1 | T2 | |||||
---|---|---|---|---|---|---|
Cognitive Domain | 1st Visit | 2nd Visit | 3rd Visit | 1st Visit | 2nd Visit | 3rd Visit |
Attention/vigilance | rs = 0.191 p = 0.406 | rs = 0.073 p = 0.761 | rs = −0.125 p = 0.657 | rs = 0.054 p = 0.838 | rs = 0.077 p = 0.768 | rs = −0.274 p = 0.343 |
Visuospatial memory and learning | rs = −0.125 p = 0.589 | rs = −0.088 p = 0.713 | rs = −0.213 p = 0.429 | rs = −0.049 p = 0.856 | rs = 0.413 p = 0.099 | rs = 0.163 p = 0.546 |
Working memory/flexibility | rs = 0.265 p = 0.246 | rs = 0.330 p = 0.155 | rs = 0.081 p = 0.783 | rs = 0.317 p = 0.232 | rs = 0.366 p = 0.148 | rs = 0.274 p = 0.344 |
Verbal memory and learning | rs = 0.134 p = 0.562 | rs = 0.184 p = 0.450 | rs = −0.229 p = 0.451 | rs = 0.031 p = 0.905 | rs = 0.109 p = 0.676 | rs = −0.100 p = 0.744 |
Speed of processing/psychomotor speed | rs = 0.269 p = 0.238 | rs = 0.358 p = 0.122 | rs = 0.391 p = 0.167 | rs = 0.263 p = 0.326 | rs = 0.272 p = 0.291 | rs = 0.228 p = 0.432 |
Abstraction/executive functions | rs = −0.050 p = 0.830 | rs = 0.066 p = 0.788 | rs = 0.432 p = 0.057 | rs = 0.440 p = 0.068 | rs = 0.394 p = 0.118 | rs = 0.407 p = 0.168 |
T1 | T2 | |||||
---|---|---|---|---|---|---|
Cognitive Domain | 1st Visit | 2nd Visit | 3rd Visit | 1st Visit | 2nd Visit | 3rd Visit |
Attention/vigilance | rs = 0.109 p = 0.637 | rs = 0.279 p = 0.234 | rs = 0.502; p = 0.057 | rs = −0.088 p = 0.721 | rs = −0.011 p = 0.966 | rs = −0.288 p = 0.298 |
Visuospatial memory and learning | rs = −0.076 p = 0.742 | rs = −0.345 p = 0.137 | rs = −0.107 p = 0.693 | rs = −0.187 p = 0.473 | rs = −0.224 p = 0.356 | rs = −0.152 p = 0.560 |
Working memory/flexibility | rs = 0.069 p = 0.767 | rs = −0.106 p = 0.656 | rs = 0.178 p = 0.542 | rs = −0.157 p = 0.547 | rs = 0.051 p = 0.843 | rs = −0.157 p = 0.576 |
Verbal memory and learning | rs = 0.414 p = 0.063 | rs = 0.137 p = 0.575 | rs = 0.148 p = 0.630 | rs = −0.245 p = 0.327 | rs = −0.332 p = 0.178 | rs = −0.077 p = 0.797 |
Speed of processing/psychomotor speed | rs = 0.116 p = 0.617 | rs = −0.071 p = 0.767 | rs = 0.191 p = 0.512 | rs = 0.066 p = 0.802 | rs = 0.168 p = 0.503 | rs = −0.211 p = 0.450 |
Abstraction/executive functions | rs = 0.541 *# p = 0.011 | rs = 0.284 p = 0.238 | rs = 0.111 p = 0.640 | rs = −0.416 p = 0.068 | rs = 0.074 p = 0.763 | rs = −0.167 p = 0.569 |
T1 | T2 | |||||
---|---|---|---|---|---|---|
Cognitive Domain | 1st Visit | 2nd Visit | 3rd Visit | 1st Visit | 2nd Visit | 3rd Visit |
Attention/vigilance | U = 37.0; p = 0.223 | U = 42.0; p = 0.594 | U = 17.0; p = 0.223 | U = 37.0; p = 0.540 | U = 35.0; p = 0.482 | U = 14.0; p = 0.118 |
Visuospatial memory and learning | U = 44.5; p = 0.479 | U = 45.0; p = 0.760 | U = 20.5; p = 0.243 | U = 31.5; p = 0.698 | U = 32.0; p = 0.340 | U = 29.5; p = 0.623 |
Working memory/flexibility | U = 51.0; p = 0.809 | U = 44.5; p = 0.732 | U = 12.0; p = 0.128 | U = 33.0; p = 0.815 | U = 35.0; p = 0.696 | U = 22.0; p = 0.536 |
Verbal memory and learning | U = 44.0; p = 0.468 | U = 35.0; p = 0.447 | U = 19.0; p = 0.836 | U = 26.0; p = 0.222 | U = 39.0; p = 0.965 | U = 8.0; p = 0.043 *# |
Speed of processing/psychomotor speed | U = 48.0; p = 0.654 | U = 47.0; p = 0.882 | U = 16.0; p = 0.318 | U = 29.0; p = 0.541 | U = 36.0; p = 0.762 | U = 23.0; p = 0.613 |
Abstraction/executive functions | U = 48.0; p = 0.641 | U = 42.5; p = 0.869 | U = 47.0; p = 0.877 | U = 40.0; p = 0.556 | U = 35.5; p = 0.500 | U = 20.0; p = 0.785 |
HAMD | U = 64.5; p = 0.951 | U = 52.5; p = 0.618 | U = 37.5; p = 0.377 | U = 48.0; p = 0.694 | U = 47.0; p = 0.969 | U = 24.0; p = 0.763 |
HAMA | U = 65.5; p = 0.999 | U = 38.5; p = 0.152 | U = 30.5; p = 0.156 | U = 51.0; p = 0.859 | U = 33.0; p = 0.261 | U = 11.0; p = 0.064 |
BDI | U = 54.5; p = 0.493 | U = 55.0; p = 0.736 | U = 24.0; p = 0.148 | U = 50.5; p = 0.829 | U = 44.5; p = 0.814 | U = 24.0; p = 0.765 |
BAI | U = 55.5; p = 0.536 | U = 58.5; p = 0.921 | U = 34.5; p = 0.265 | U = 41.5; p = 0.391 | U = 25.5; p = 0.134 | U = 19.5; p = 0.401 |
Appendix B
Type of Treatment | Counts | % of Total | Cumulative % |
---|---|---|---|
ABVD | 13 | 29.5% | 29.5% |
6× BEACOPP | 21 | 47.7% | 77.3% |
ABVD and 2× BEACOPP | 10 | 22.7% | 100% |
Cognitive Domain | Treatment | 1st Visit M (SD) | 2nd Visit M (SD) | 3rd Visit M (SD) | Friedman Test | Within Group Differences (Significant) | Between Group Differences: Kruskal–Wallis |
---|---|---|---|---|---|---|---|
Attention/vigilance | T1 | 0.150 (0.543) | 0.346 (0.235) | 0.295 (0.247) | X2 = 0.33, p = 0.846 | 1.v: X2 = 0.075 p = 0.963 2.v: X2 = 0.687 p = 0.709 3.v: X2 = 0.114 p = 0.945 | |
T2 | 0.123 (0.445) | 0.249 (0.297) | 0.825 (1.77) | X2 = 1.60, p = 0.449 | |||
T3 | 0.617 (1.56) | 0.256 (0.307) | 0.349 (0.269) | X2 = 3.56, p = 0.169 | |||
Visuospatial memory and learning | T1 | 0.364 (0.977) | 0.450 (1.38) | 0.881 (1.77) | X2 = 3.22, p = 0.200 | 1.v: X2 = 2.04 p = 0.360 2.v: X2 = 5.45 p = 0.065 3.v: X2 = 0.585 p = 0.746 | |
T2 | 0.00 (0.648) | 0.991 (1.06) | 0.627 (1.87) | X2 = 7.75, p = 0.021 | 1–2 * 1–3 * | ||
T3 | 0.417 (0.904) | 0.033 (1.02) | 1.43 (0.722) | X2 = 10.9, p = 0.004 | 1– 3 ** 2–3 *** | ||
Working memory/flexibility | T1 | −0.303 (0.861) | −0.090 (0.917) | −0.157 (0.822) | X2 = 2.80, p = 0.247 | 1.v: X2 = 0.549 p = 0.760 2.v: X2 = 0.116 p = 0.944 3.v: X2 = 0.681 p = 0.711 | |
T2 | −0.304 (0.495) | −0.013 (0.537) | −0.049 (0.703) | X2 = 8.40, p = 0.015 | 1–2 *# 1–3 ** | ||
T3 | −0.270 (0.386) | −0.051 (0.452) | 0.220 (0.578) | X2 = 4.67, p = 0.097 | 1–3 *# | ||
Verbal memory and learning | T1 | −0.121 (0.927) | −0.225 (0.834) | −0.205 (0.438) | X2 = 1.50, p = 0.472 | 1.v: X2 = 1.64 p = 0.440 2.v: X2 = 0.917 p = 0.632 3.v: X2 = 0.926 p = 0.629 | |
T2 | −0.528 (0.815) | −0.266 (0.575) | 0.052 (0.565) | X2 = 7.43, p = 0.024 | 1–3 ** 1–3 *# | ||
T3 | −0.366 (0.974) | −0.091 (0.666) | 0.088 (0.629) | X2 = 4.67, p = 0.097 | 1–3 *# | ||
Speed of processing/psychomotor speed | T1 | −0.495 (0.773) | −0.379 (0.915) | −0.160 (1.28) | X2 = 4.80, p = 0.091 | 1–2 *# 1–3 *# | 1.v: X2 = 1.80 p = 0.408 2.v: X2 = 0.828 p = 0.661 3.v: X2 = 0.288 p = 0.866 |
T2 | −0.364 (0.561) | −0.150 (0.591) | −0.083 (0.850) | X2 = 9.73, p = 0.008 | 1–2 *# 1–3 *** | ||
T3 | −0.610 (0.456) | −0.310 (0.446) | −0.165 (0.614) | X2 = 8.00, p = 0.018 | 1–3 ** | ||
Abstraction/executive functions | T1 | −0.222 (0.592) | 0.142 (0.686) | −0.262 (0.792) | X2 = 7.80, p = 0.020 | 1–2 *# 2–3 ** | 1.v: X2 = 2.73 p = 0.256 2.v: X2 = 4.79 p = 0.091 3.v: X2 = 1.07 p = 0.586 |
T2 | −0.567 (0.831) | −0.421 (0.637) | −0.500 (0.894) | X2 = 3.45, p = 0.178 | |||
T3 | −0.593 (0.619) | −0.291 (0.786) | −0.542 (0.542) | X2 = 3.27, p = 0.195 |
Variables | Visit | Group 1 Mean (SD) | Group 2 Mean (SD) | Group 3 Mean (SD) | Between-Group Differences: Kruskal–Wallis | Within-Groups: Friedman | Significant Within Groups |
---|---|---|---|---|---|---|---|
HAMD | 1st | 6.69 (5.68) | 6.71 (5.47) | 6.70 (4.30) | X2 = 0.025; p = 0.988 | G1: X2 = 3.57, p = 0.168 G2: X2 = 6.33, p = 0.042 G3: X2 = 4.67, p = 0.097 | G2: 1–2 *# 1–3 **# |
2nd | 2.50 (2.71) | 3.60 (4.03) | 3.30 (2.67) | X2 = 1.22; p = 0.543 | |||
3rd | 3.36 (2.62) | 3.27 (3.59) | 3.67 (4.90) | X2 = 0.294; p = 0.863 | |||
HAMA | 1st | 7.23 (4.60) | 7.38 (5.20) | 6.30 (4.08) | X2 = 0.183; p = 0.912 | G1: X2 = 4.76, p = 0.092 G2: X2 = 4.93, p = 0.085 G3: X2 = 1.65, p = 0.439 | |
2nd | 3.33 (4.19) | 5.00 (3.67) | 4.10 (3.25) | X2 = 2.45; p = 0.294 | |||
3rd | 5.00 (4.92) | 4.20 (4.39) | 4.56 (7.04) | X2 = 0.847; p = 0.655 | |||
BAI | 1st | 6.85 (5.21) | 8.52 (6.10) | 6.50 (4.45) | X2 = 0.753; p = 0.686 | G1: X2 = 4.44, p = 0.109 G2: X2 = 12.6, p = 0.002 G3: X2 = 4.17, p = 0.124 | G2: 1–2 * 1–3 *** |
2nd | 4.00 (4.16) | 7.16 (5.79) | 4.30 (3.80) | X2 = 3.67; p = 0.159 | |||
3rd | 3.36 (2.16) | 4.53 (5.07) | 4.44 (4.19) | X2 = 0.183; p = 0.912 | |||
BDI | 1st | 2.62 (2.33) | 4.05 (4.03) | 3.20 (2.49) | X2 = 0.959; p = 0.619 | G1: X2 = 0.154, p = 0.926 G2: X2 = 0.156, p = 0.925 G3: X2 = 2.95, p = 0.229 | |
2nd | 2.00 (1.81) | 3.75 (3.93) | 2.80 (2.44) | X2= 1.42; p = 0.492 | |||
3rd | 2.00 (1.41) | 2.93 (2.60) | 1.29 (1.38) | X2= 2.16; p = 0.340 |
References
- Juríčková, V.; Fayette, D.; Jonáš, J.; Fajnerová, I.; Kozák, T.; Horáček, J. Pretreatment Cancer-Related Cognitive Impairment in Hodgkin Lymphoma Patients. Curr. Oncol. 2023, 30, 9028–9038. [Google Scholar] [CrossRef] [PubMed]
- Fayette, D.; Juríčková, V.; Kozák, T.; Mociková, H.; Gaherová, L.; Fajnerová, I.; Horáček, J. Cognitive impairment associated with Hodgkin’s lymphoma and chemotherapy. Neurosci. Lett. 2023, 797, 137082. [Google Scholar] [CrossRef] [PubMed]
- Krull, K.R.; Sabin, N.D.; Reddick, W.E.; Zhu, L.; Armstrong, G.T.; Green, D.M.; Arevalo, A.R.; Krasin, M.J.; Srivastava, D.K.; Robison, L.L.; et al. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. J. Clin. Oncol. 2012, 29, 3618–3624. [Google Scholar] [CrossRef] [PubMed]
- Trachtenberg, E.; Mashiach, T.; Hayun, B.R.; Tadmor, T.; Fisher, T.; Aharon-Peretz, J.; Dann, E.J. Cognitive impairment in Hodgkin lymphoma survivors. Br. J. Haematol. 2018, 182, 670–678. [Google Scholar] [CrossRef]
- Vinokurova, E.G.; Marchenko, A.A.; Khrushchev, S.O.; Olexenko, L.V.; Rupchev, G.E.; Vybornykh, D.E.; Moiseeva, T.N. Cognitive impairments in patients with Hodgkin’s lymphoma. HemaSphere 2018, 2, 22–23. [Google Scholar]
- Magyari, F.; Ivanka, T.; Egerhazi, A.; Simon, Z.; Miltenyi, Z.; Kosa, K.; Illes, A. Cognitive dysfunction after treatment for Hodgkin lymphoma. HemaSphere 2018, 2, 22. [Google Scholar] [CrossRef]
- Ansell, S.M. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2018, 93, 704–715. [Google Scholar] [CrossRef]
- Engert, A. ABVD or BEACOPP for Advanced Hodgkin Lymphoma. JCO 2016, 34, 1167–1169. [Google Scholar] [CrossRef]
- Viviani, S.; Zinzani, P.L.; Rambaldi, A.; Brusamolino, E.; Levis, A.; Bonfante, V.; Vitolo, U.; Pulsoni, A.; Liberati, A.M.; Specchia, G.; et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. N. Engl. J. Med. 2011, 365, 203–212. [Google Scholar] [CrossRef]
- Merli, F.; Luminari, S.; Gobbi, P.G.; Cascavilla, N.; Mammi, C.; Ilariucci, F.; Stelitano, C.; Musso, M.; Baldini, L.; Galimberti, S.; et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients with Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J. Clin. Oncol. 2016, 34, 1175–1181. [Google Scholar] [CrossRef]
- Skoetz, N.; Will, A.; Monsef, I.; Brillant, C.; Engert, A.; von Tresckow, B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavorable or advanced stage Hodgkin lymphoma. Cochrane Database Syst. Rev. 2017, 5, CD007941. [Google Scholar] [CrossRef] [PubMed]
- Skurlova, M.; Holubova, K.; Kleteckova, L.; Kozak, T.; Kubova, H.; Horacek, J.; Vales, K. Chemobrain in blood cancers: How chemotherapeutics interfere with the brain’s structure and functionality, immune system, and metabolic functions. Med. Res. Rev. 2024, 44, 5–22. [Google Scholar] [CrossRef] [PubMed]
- Preiss, M. Neuropsychologická Baterie Psychiatrického Centra Praha: Klinické Vyšetření Základních Kognitivních Funkcí, 3rd ed.; Psychiatrické Centrum Praha: Praha, Czech Republic, 2012; p. 158. [Google Scholar]
- Conners, C.K. Conners Continuous Performance Test (Conners CPT 3™) & Conners Continuous Auditory Test of Attention (Conners CATA™), 3rd ed.; Multi-Health Systems Inc.: Toronto, ON, Canada, 2015. [Google Scholar]
- Černochová, D.; Goldmann, P.; Král, P.; Soukupová, T.; Šnorek, V.; Havlůj, V. Wechslerova Inteligenční Škála pro Dospělé. Hogrege-Testcentrum: Praha, Czech Republic, 2010. [Google Scholar]
- Krivá, L’. Stroopův Test; Hogrefe-Testcentrum: Praha, Czech Republic, 2013. [Google Scholar]
- Loring, W.; Meador, K.J. The Medical College of Georgia (MCG) Complex Figures. In The Handbook of Rey-Osterrieth Complex Figure Usage: Clinical and Research Applications; Knight, J.A., Kaplan, E., Eds.; Psychological Assessment Resources, Inc.: Odessa, FL, USA, 1989; pp. 313–321. [Google Scholar]
- Øvlisen, A.K.; Jakobsen, L.H.; Kragholm, K.H.; Nielsen, R.E.; Hutchings, M.; Dahl-Sørensen, R.B.; Frederiksen, H.; Stoltenberg, D.; Bøgsted, M.; Østgård, L.S.G.; et al. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Med. 2020, 9, 4395–4404. [Google Scholar] [CrossRef]
- Mitchell, A.J.; Chan, M.; Bhatti, H.; Haltom, M.; Grassi, L.; Johansen, C.; Meader, N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol. 2011, 12, 160–174. [Google Scholar] [CrossRef]
- Hinz, A.; Krauss, O.; Hauss, J.P.; Höckel, M.; Kortmann, R.D.; Stolzenburg, J.U.; Schwarz, R. Anxiety and depression in cancer patients compared with the general population. Eur. J. Cancer Care 2010, 19, 522–529. [Google Scholar] [CrossRef]
- Linendoll, N.; Saunders, T.; Burns, R.; Nyce, J.D.; Wendell, K.B.; Evens, A.M.; Parsons, S.K. Health-related quality of life in Hodgkin lymphoma: A systematic review. HRQOL 2016, 14, 114. [Google Scholar] [CrossRef]
- Kreissl, S.; Müller, H.; Goergen, H.; Meissner, J.; Topp, M.; Sökler, M.; Markova, J.; Bernhard, J.; Greil, R.; von Tresckow, B.; et al. Health-Related Quality of Life in Patients with Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. J. Clin. Oncol. 2020, 38, 2839–2848. [Google Scholar] [CrossRef]
- Airaksinen, E.; Larssin, M.; Lundberg, I.; Forsell, Y. Kognitivní funkce u depresivních poruch: Důkazy z populační studie. Psychol. Med. 2004, 34, 83–91. [Google Scholar] [CrossRef]
- Salthouse, T.A. How general are the effects of trait anxiety and depressive symptoms on cognitive functioning? Emotion 2012, 12, 1075. [Google Scholar] [CrossRef]
- Ptáček, J.; Raboch, J.; Vnuková, J.; Hlinka, J.; Červenková, M. Standardization of Czech version of Beck depression inventory (BDI-II). Eur. Psychiatry 2017, 41, S539. [Google Scholar] [CrossRef]
- Kamaradova, D.; Prasko, J.; Latalova, K.; Panackova, L.; Svancara, J.; Grambal, A.; Sigmundova, Z.; Ociskova, M.; Bares, V.; Cakirpaloglu, S.; et al. Psychometric properties of the Czech version of the Beck Anxiety Inventory–comparison between diagnostic groups. Neuroendocrinol. Lett. 2015, 36, 706–712. [Google Scholar] [PubMed]
- Hamilton, M. Hamilton depression rating scale (HAM-D). J. Neurol. Neurosurg. Psychiatry 1960, 23, 56–62. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, M. The assessment of anxiety states by rating. Br. J. Health Psychol. 1959, 32, 50–55. [Google Scholar] [CrossRef] [PubMed]
- Dragomirecka, E. Czech version of the World Health Organization Quality of Life (WHOQOL)–Translation and designing the response scales. Psychiatrie 2006, 10, 68–73. [Google Scholar]
- Baudino, B.; D’agata, F.; Caroppo, P.; Castellano, G.; Cauda, S.; Manfredi, M.; Geda, E.; Castelli, L.; Mortara, P.; Orsi, L.; et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q. J. Nucl. Med. Mol. Imaging 2012, 56, 559–568. [Google Scholar]
- Magyari, F.; Virga, I.; Simon, Z.; Miltényi, Z.; Illés, A.; Kósa, K.; Ivánka, T.; Berecz, R.; Égerházi, A.; Illés, Á. Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary. Support. Care Cancer 2022, 30, 5249–5258. [Google Scholar] [CrossRef]
Group 1 | Group 2 | Group Difference | ||
---|---|---|---|---|
HL stage | Early | 13 | 0 | - |
Intermediate | 10 | 0 | - | |
Advanced | 0 | 21 | - | |
Age | M = 37.5; SD = 14.0; 21–67 | M = 36.3; SD = 9.27; 19–54 | p = 0.798 | |
Sex | Male | 12 | 12 | p = 0.075 |
Female | 11 | 9 | ||
Education | Elementary school | 0 (0%) | 3 (15.8%) | p = 0.798 |
Certificate of apprenticeship | 2 (8.7%) | 3 (15.8%) | ||
High school education | 13 (56.5%) | 9 (47.4%) | ||
University degree | 7 (30.4%) | 4 (21.1%) | ||
Post-doctoral education | 1 (4.3%) | 0 (0%) |
Cognitive Domain | Group | 1st Visit M (SD) | 2nd Visit M (SD) | 3rd Visit M (SD) | Friedman Test | Within-Group Differences (Significant) |
---|---|---|---|---|---|---|
Attention/vigilance | Patients | 0.254 (0.878) | 0.275 (0.281) | 0.576 (1.27) | X2 = 4.47, p = 0.107 | 1–3 *# |
Controls | 0.32 (0.41) | 0.68 (1.23) | 0.44 (0.34) | X2 = 8.77, p = 0.012 | 1–3 *# | |
Visuospatial memory and learning | Patients | 0.215 (0.823) | 0.607 (1.18) | 0.899 (1.61) | X2 = 15.1, p ≤ 0.001 | 1–3 *** 2–3 ** |
Controls | 0.36 (1.01) | 1.16 (1.08) | 1.44 (1.15) | X2 = 40.26, p < 0.001 | 1–2 ***, 1–3 ***, 2–3 *# | |
Working memory/flexibility | Patients | −0.295 (0.586) | −0.043 (0.623) | 0.016 (0.678) | X2 = 15.0, p ≤ 0.001 | 1–2 ** 1–3 *** |
Controls | 0.00 (0.78) | 0.20 (0.74) | 0.15 (0.84) | X2 = 5.57, p = 0.062 | 1–2 ** | |
Verbal memory and learning | Patients | −0.372 (0.882) | −0.209 (0.654) | 0.026 (0.560) | X2 = 13.4, p = 0.001 | 1–3 *** 2–3 ** |
Controls | 0.36 (0.59) | 0.24 (0.73) | 0.55 (0.68) | X2 = 5.02, p = 0.081 | 1–3 **, 2–3 ** | |
Speed of processing/psychomotor speed | Patients | −0.467 (0.599) | −0.252 (0.650) | −0.122 (0.840) | X2 = 21.6, p ≤ 0.001 | 1–2 ***, 1–3 *** 2–3 *# |
Controls | −0.02 (0.63) | 0.16 (0.62) | 0.28 (0.71) | X2 = 10.71, p = 0.005 | 1–2 *,1–3 ***, 2–3 ** | |
Abstraction/executive functions | Patients | −0.472 (0.726) | −0.231 (0.708) | −0.434 (0.769) | X2 = 11.9, p = 0.003 | 1–2 *** 2–3 ** |
Controls | 0.55 (0.72) | 0.22 (0.97) | 0.47 (0.74) | X2 = 4.76, p = 0.092 |
Cognitive Domain | Treatment | 1st Visit M (SD) | 2nd Visit M (SD) | 3rd Visit M (SD) | Friedman Test | Within-Group Differences (Significant) | Between-Group Differences Mann–Whitney U Test |
---|---|---|---|---|---|---|---|
Attention/vigilance | T1 | 0.372 (1.14) | 0.301 (0.270) | 0.328 (0.253) | X2 = 3.33, p = 0.189 | 1. v: U = 194.0 p = 0.450 2. v: U = 170.0 p = 0.583 3. v: U = 109.0 p = 0.884 | |
T2 | 0.123 (0.445) | 0.249 (0.297) | 0.825 (1.77) | X2 = 4.47, p = 0.107 | |||
Visuospatial memory and learning | T1 | 0.389 (0.919) | 0.242 (1.20) | 1.19 (1.27) | X2 = 13.7, p = 0.001 | 1–3 *** 2–3 *** | 1. v: U = 131.0 p = 0.161 2. v: U = 124.0 p = 0.062 3. v: U = 117.0 p = 0.502 |
T2 | 0.00 (0.648) | 0.991 (1.06) | 0.627 (1.87) | X2 = 7.75, p = 0.021 | 1–2 ** 1–3 ** | ||
Working memory/flexibility | T1 | −0.287 (0.662) | −0.070 (0.704) | 0.086 (0.670) | X2 = 7.0, p = 0.030 | 1–3 ** | 1. v: U = 160.0 p = 0.601 2. v: U = 169.0 p = 0.748 3. v: U = 95.5 p = 0.694 |
T2 | −0.304 (0.495) | −0.013 (0.537) | −0.049 (0.703) | X2 = 8.40, p = 0.015 | 1–2 **# 1–3 ** | ||
Verbal memory and learning | T1 | −0.238 (0.934) | −0.154 (0.732) | −0.002 (0.576) | X2 = 6.00, p = 0.050 | 1–3 ** | 1. v: U = 148.0 p = 0.257 2. v: U = 152.0 p = 0.574 3. v: U = 90.0 p = 0.981 |
T2 | −0.528 (0.815) | −0.266 (0.575) | 0.052 (0.565) | X2 = 7.43, p = 0.024 | 1–3 ** 2–3 *# | ||
Speed of processing/psychomotor speed | T1 | −0.550 (0.629) | −0.344 (0.701) | −0.164 (0.859) | X2 = 12.0, p = 0.002 | 1–2 ** 1–3 *** | 1. v: U = 138.0. p = 0.243 2. v: U = 150.0 p = 0.393 3. v: U = 99.0 p = 0.813 |
T2 | −0.364 (0.561) | −0.150 (0.591) | −0.083 (0.850) | X2 = 9.73, p = 0.008 | 1–2 *# 1–3 *** | ||
Abstraction/executive functions | T1 | −0.381 (0.617) | −0.041 (0.742) | −0.388 (0.689) | X2 = 9.68, p = 0.008 | 1–2 ** 2–3 ** | 1. v: U = 164.0 p = 0.223 2. v: U = 124.0 p = 0.097 3. v: U = 113.0 p = 0.338 |
T2 | −0.567 (0.831) | −0.421 (0.637) | −0.500 (0.894) | X2 = 3.45, p = 0.178 |
Variables | Visit | Group 1 Mean (SD) | Group 2 Mean (SD) | Between-Group Differences Mann–Whitney U Test | Within-Groups: Friedman | Significance Within Groups |
---|---|---|---|---|---|---|
HAMD | 1st | 6.70 (5.01) | 6.71 (5.47) | U = 241.0; p = 0.999 | G1: X2 = 7.92, p = 0.019 G2: X2 = 6.33, p = 0.042 | G1: 1–2 *# 1–3 ** G2: 1–2 *# 1–3 **# |
2nd | 2.86 (2.66) | 3.60 (4.03) | U = 211.0; p = 0.828 | |||
3rd | 3.50 (3.71) | 3.27 (3.59) | U = 142.0; p = 0.787 | |||
HAMA | 1st | 6.83 (4.31) | 7.38 (5.20) | U = 235.0; p = 0.888 | G1: X2 = 5.47, p = 0.065 G2: X2 = 4.93, p = 0.085 | |
2nd | 3.68 (3.72) | 5.00 (3.67) | U = 166.0; p = 0.170 | |||
3rd | 4.80 (5.80) | 4.20 (4.39) | U = 147.0; p = 0.933 | |||
BAI | 1st | 6.70 (4.79) | 8.52 (6.10) | U = 205.0; p = 0.396 | G1: X2 = 8.13, p = 0.017 G2: X2 = 12.6, p = 0.002 | G1: 1–2 *# 1–3 ** G2: 1–2 * 1–3 *** |
2nd | 4.14 (3.91) | 7.16 (5.79) | U = 137.0; p = 0.058 | |||
3rd | 3.85 (3.18) | 4.53 (5.07) | U = 140.0; p = 0.749 | |||
BDI | 1st | 2.87 (2.36) | 4.05 (4.03) | U = 207.0; p = 0.413 | G1: X2 = 1.03, p = 0.597 G2: X2 = 0.154, p = 0.926 | |
2nd | 2.36 (2.11) | 3.75 (3.93) | U = 182.0; p = 0.336 | |||
3rd | 1.72 (1.41) | 2.93 (2.60) | U = 104.0; p = 0.254 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fayette, D.; Juríčková, V.; Fajnerová, I.; Horáček, J.; Kozák, T. The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients. Cancers 2025, 17, 1488. https://doi.org/10.3390/cancers17091488
Fayette D, Juríčková V, Fajnerová I, Horáček J, Kozák T. The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients. Cancers. 2025; 17(9):1488. https://doi.org/10.3390/cancers17091488
Chicago/Turabian StyleFayette, Dan, Veronika Juríčková, Iveta Fajnerová, Jiří Horáček, and Tomáš Kozák. 2025. "The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients" Cancers 17, no. 9: 1488. https://doi.org/10.3390/cancers17091488
APA StyleFayette, D., Juríčková, V., Fajnerová, I., Horáček, J., & Kozák, T. (2025). The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients. Cancers, 17(9), 1488. https://doi.org/10.3390/cancers17091488